← All Zeo Scientifix, INC filings

Zeo Scientifix, INC 8-K filings

OQB
ZEOX
Zeo Scientifix, INC
8-K/A: Zeo ScientifiX Amends 8-K Filing to Correct Presentation on New Hair Growth Product
Zeo ScientifiX has amended its previous 8-K filing to correct graphical errors in a PowerPoint presentation related to their new hair growth product, ZEO HAIR GROW Powered By Exotropin.
OQB
ZEOX
Zeo Scientifix, INC
8-K: Zeo ScientifiX Showcases Hair Growth Product at Medical Aesthetics Meeting
Zeo ScientifiX, in collaboration with Exotropin, is introducing its new hair growth product, ZEO HAIR GROW Powered By Exotropin, at the Medical Aesthetics Professionals meeting.
OQB
ZEOX
Zeo Scientifix, INC
8-K: ZEO ScientifiX and Exotropin Launch Hair Loss Solution at Medical Aesthetics Conference
ZEO ScientifiX and Exotropin are launching their collaborative hair growth product, ZEO HAIR GROW Powered By Exotropin, at the Medical Aesthetics Professionals meeting in Scottsdale, Arizona.
OQB
ZEOX
Zeo Scientifix, INC
8-K: ZEO ScientifiX Launches Regenerative Medicine Educational Series for Healthcare Providers
ZEO ScientifiX, a South Florida-based biopharmaceutical company, has announced the launch of a monthly educational series focused on regenerative medicine for healthcare providers.
OQB
ZEOX
Zeo Scientifix, INC
8-K: ZEO ScientifiX Partners with Physicians Group to Advance Clinical Trials
ZEO ScientifiX has partnered with Physicians Group, a large multi-state provider organization, to collaborate on clinical trials and expand the reach of their therapeutic products.
OQB
ZEOX
Zeo Scientifix, INC
8-K: Zeo ScientifiX Advances to Phase 2 Clinical Trials, Targeting $175 Billion Regenerative Medicine Market
Biopharmaceutical company Zeo ScientifiX announced it is preparing to launch Phase 2 clinical trials for its flagship product, Zofin, following successful Phase 1 trials, positioning itself to capitalize on the rapidly growing regenerative medicine market.
OQB
ZEOX
Zeo Scientifix, INC
8-K: Zeo ScientifiX Grants Equity to Consultants and Executives
Zeo ScientifiX granted warrants and stock options to consultants and executive officers on July 11, 2024.
OQB
ZEOX
Zeo Scientifix, INC
8-K: Zeo ScientifiX Secures $500,000 in Private Financing, Enters Supply Agreement
Zeo ScientifiX has completed a $500,000 private financing round, issuing shares and warrants to a single accredited investor, and has also entered into a supply agreement with an affiliate of the investor.
OQB
ZEOX
Zeo Scientifix, INC
8-K: Zeo ScientifiX Announces Departure of CEO and CSO, Appoints Interim CEO
Zeo ScientifiX has not renewed the employment agreements of its CEO and CSO, and has appointed the CFO as interim CEO.
OQB
ZEOX
Zeo Scientifix, INC
8-K: Zeo ScientifiX Awards Stock Grants and Options to Directors, Increases CFO Salary
Zeo ScientifiX granted stock awards and options to its board members and increased the base salary of its Chief Financial Officer.
OQB
ZEOX
Zeo Scientifix, INC
8-K: Zeo ScientifiX Inc. Announces Name and Ticker Change, Trading Under ZEOX
Zeo ScientifiX, formerly Organicell Regenerative Medicine, has completed its corporate rebranding, with its stock trading under the new ticker ZEOX starting March 5, 2024.
OQB
ZEOX
Zeo Scientifix, INC
8-K: Organicell Regenerative Medicine Rebrands as Zeo ScientifiX, Inc.
Organicell Regenerative Medicine, Inc. has officially changed its name to Zeo ScientifiX, Inc., effective February 20, 2024.